Evidence map›Paper›PMID 42038656›Full record

ArticleClinical case reports2026

Flecainide-Induced Interstitial Lung Disease: A Case Report and Review of the Literature.

Elizabeth Jenkins, John McGinty, Brian Skinner

Abstract read
In one paragraph

Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Elizabeth JenkinsReid Health Richmond Indiana USA.ORCID https://orcid.org/0009-0009-9264-9723
John McGintyReid Health Richmond Indiana USA.
Brian SkinnerMarian University Tom & Julie Wood College of Osteopathic Medicine Indianapolis Indiana USA.ORCID https://orcid.org/0000-0003-3814-7887

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This case describes a rare adverse effect in which the subject developed interstitial lung disease after initiating a class IC antiarrhythmic, flecainide. There is no current treatment recommendation for flecainide-induced interstitial lung disease. Previously reported cases were successful with discontinuation of the offending drug and initiation of systemic corticosteroids; however, this patient did not respond to this treatment plan, resulting in death. Obtaining a thorough patient history regarding new medications and the start of symptoms played a crucial role when creating a differential diagnosis for this case.

Indexed as

adverse drug eventsantiarrhythmicflecainideinterstitial lung diseasepulmonary toxicity

Identifiers

PMID42038656
PMCPMC13108409

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.